Novartis to Acquire Avidity Biosciences for $12 Billion

October 29, 2025
Novartis has agreed to acquire Avidity Biosciences for approximately $12 billion in cash, with the deal expected to close in the first half of 2026 following the planned separation of Avidity’s early-stage cardiology programs into a new company called SpinCo.

Novartis will acquire Avidity Biosciences for approximately $12 billion in cash, announced in a press release. Under the terms of the agreement, Avidity shareholders will receive $72.00 per share, representing a 46% premium over Avidity’s October 24, 2025 closing price.

The acquisition, unanimously approved by both companies’ boards, is expected to close in the first half of 2026, subject to regulatory and shareholder approvals. Completion is also contingent on the separation of Avidity’s early-stage precision cardiology programs into a new publicly traded company, SpinCo.

SpinCo will be led by Kathleen Gallagher, currently Avidity’s chief program officer, as chief executive officer, with Avidity CEO Sarah Boyce serving as chair of the board. The new entity will focus on programs targeting rare genetic cardiomyopathies, including AOC 1086 and AOC 1072.

Through the acquisition, Novartis will gain Avidity’s neuroscience programs and its RNA-targeting delivery platform, including three late-stage clinical programs for Duchenne muscular dystrophy, myotonic dystrophy type 1, and facioscapulohumeral muscular dystrophy.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

AI Funding News Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Funding

10/29
ATDev Raises $3 Million Seed Funding to Expand Assistive Mobility Ecosystem
10/29
The Bot Company Plans $250 Million Raise at $4 Billion Valuation
10/29
Generation Lab Raises $11M Seed Round for SystemAge Longevity Platform
10/29
Fourier Health Raises $8.4M to Streamline Clinical Data Processing with AI
10/29
Opyn Health Acquires AI Benefits Platform Empara

More from: Life Sciences

10/29
ExaCare AI Raises $30M Series A to Expand AI Platform for Skilled Nursing Facilities
10/29
Harbour BioMed Launches Fully Human Generative AI HCAb Model
10/29
MCG Health and Allegheny Health Network to Present on AI in Utilization Management at ACMA 2025
10/29
CareSet Names Sepideh Naseri Chief Data and Analytics Officer
10/29
ID.me and Flexpa Partner to Strengthen Health Data Access and Security

Subscribe to AI Funding Brief

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like